SCINTIMUN® 1 mg
|
| Isotope | Technetium (99mTc) |
| Number of labelling sets | 2 |
| Each vial 1 contains 5.02 mg dry substance : Besilesomab Disodium hydrogen phosphate, anhydrous Sodium dihydrogen phosphate, anhydrous Under nitrogen atmosphere Sorbitol E420 Each vial 2 contains 3 mg dry substance : 1,1,3,3-propane tetraphosphonic acid, tetrasodium salt, dihydrate (PTP) Tin (II) chloride dihydrate Sodium hydroxyde 1N (pH adjustment) Hydrochloric acid 1N (pH adjustment) Under nitrogen atmosphere |
1 mg 1.42 mg 0.60 mg 2 mg 2.7 mg 0.12 mg |
| Volume of pertechnetate 99mTc to use for reconstitution | 2 to 7 mL |
| Radiochemical purity | ≥ 95 % |
| Storage | 2 years at 2 - 8°C |
| Stability of labelled product | 3 h at 2-8°C Protected from light and atmospheric oxygen |
| Activity per vial | 300 to 1800 MBq |
| Indications / Posology | Detection of location of infectious/inflammatory lesions (400-800 MBq) Bone marrow scintigraphy (200 - 400 MBq) |
| Time between injection and examination | 3 to 6 h and late image 24 h |
| Availability | From stock |